Nonmercaptalbumin as an oxidative stress marker in Parkinson’s and PARK2 disease
Abstract Objective To investigate the oxidized albumin ratio, which is the redox ratio of human nonmercaptalbumin (HNA) to serum albumin (%HNA), as a biomarker in idiopathic Parkinson’s disease (iPD) and related neurodegenerative disorders. Methods This prospective study enrolled 216 iPD patients, 1...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-03-01
|
Series: | Annals of Clinical and Translational Neurology |
Online Access: | https://doi.org/10.1002/acn3.50990 |
id |
doaj-e9eda1b5376749098574688418ee6a8b |
---|---|
record_format |
Article |
spelling |
doaj-e9eda1b5376749098574688418ee6a8b2021-05-02T21:13:20ZengWileyAnnals of Clinical and Translational Neurology2328-95032020-03-017330731710.1002/acn3.50990Nonmercaptalbumin as an oxidative stress marker in Parkinson’s and PARK2 diseaseShin‐Ichi Ueno0Taku Hatano1Ayami Okuzumi2Shinji Saiki3Yutaka Oji4Akio Mori5Takahiro Koinuma6Motoki Fujimaki7Haruka Takeshige‐Amano8Akihide Kondo9Naoyuki Yoshikawa10Takahiro Nojiri11Makoto Kurano12Keiko Yasukawa13Yutaka Yatomi14Hitoshi Ikeda15Nobutaka Hattori16Department of Neurology Faculty of Medicine Juntendo University Tokyo JapanDepartment of Neurology Faculty of Medicine Juntendo University Tokyo JapanDepartment of Neurology Faculty of Medicine Juntendo University Tokyo JapanDepartment of Neurology Faculty of Medicine Juntendo University Tokyo JapanDepartment of Neurology Faculty of Medicine Juntendo University Tokyo JapanDepartment of Neurology Faculty of Medicine Juntendo University Tokyo JapanDepartment of Neurology Faculty of Medicine Juntendo University Tokyo JapanDepartment of Neurology Faculty of Medicine Juntendo University Tokyo JapanDepartment of Neurology Faculty of Medicine Juntendo University Tokyo JapanDepartment of Neurosurgery Faculty of Medicine Juntendo University Tokyo JapanDepartment of Clinical Laboratory The University of Tokyo Hospital Tokyo JapanDepartment of Clinical Laboratory The University of Tokyo Hospital Tokyo JapanDepartment of Clinical Laboratory The University of Tokyo Hospital Tokyo JapanDepartment of Clinical Laboratory The University of Tokyo Hospital Tokyo JapanDepartment of Clinical Laboratory Medicine Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Clinical Laboratory Medicine Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Neurology Faculty of Medicine Juntendo University Tokyo JapanAbstract Objective To investigate the oxidized albumin ratio, which is the redox ratio of human nonmercaptalbumin (HNA) to serum albumin (%HNA), as a biomarker in idiopathic Parkinson’s disease (iPD) and related neurodegenerative disorders. Methods This prospective study enrolled 216 iPD patients, 15 patients with autosomal recessive familial PD due to parkin mutations (PARK2), 30 multiple system atrophy (MSA) patients, 32 progressive nuclear palsy (PSP) patients, and 143 healthy controls. HNA was analyzed using modified high‐performance liquid chromatography and was evaluated alongside other parameters. Results iPD and PARK2 patients had a higher %HNA than controls (iPD vs. controls: odds ratio (OR) 1.325, P < 0.001; PARK2 vs. controls: OR 1.712, P < 0.001). Even iPD patients at an early Hoehn & Yahr stage (I and II) showed a higher %HNA than controls. iPD patients had a higher %HNA than MSA and PSP patients (iPD vs. MSA: OR 1.249, P < 0.001, iPD vs. PSP: OR 1.288, P < 0.05). When discriminating iPD patients from controls, %HNA corrected by age achieved an AUC of 0.750; when discriminating iPD patients from MSA and PSP patients, an AUC of 0.747 was achieved. Furthermore, uric acid, an antioxidant compound, was decreased in iPD patients, similar to the change in %HNA. Interpretation %HNA was significantly increased in iPD and PARK2 patients compared with controls, regardless of disease course and severity. Oxidative stress might be increased from the early stages of iPD and PARK2 and play an important role in their pathomechanisms.https://doi.org/10.1002/acn3.50990 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shin‐Ichi Ueno Taku Hatano Ayami Okuzumi Shinji Saiki Yutaka Oji Akio Mori Takahiro Koinuma Motoki Fujimaki Haruka Takeshige‐Amano Akihide Kondo Naoyuki Yoshikawa Takahiro Nojiri Makoto Kurano Keiko Yasukawa Yutaka Yatomi Hitoshi Ikeda Nobutaka Hattori |
spellingShingle |
Shin‐Ichi Ueno Taku Hatano Ayami Okuzumi Shinji Saiki Yutaka Oji Akio Mori Takahiro Koinuma Motoki Fujimaki Haruka Takeshige‐Amano Akihide Kondo Naoyuki Yoshikawa Takahiro Nojiri Makoto Kurano Keiko Yasukawa Yutaka Yatomi Hitoshi Ikeda Nobutaka Hattori Nonmercaptalbumin as an oxidative stress marker in Parkinson’s and PARK2 disease Annals of Clinical and Translational Neurology |
author_facet |
Shin‐Ichi Ueno Taku Hatano Ayami Okuzumi Shinji Saiki Yutaka Oji Akio Mori Takahiro Koinuma Motoki Fujimaki Haruka Takeshige‐Amano Akihide Kondo Naoyuki Yoshikawa Takahiro Nojiri Makoto Kurano Keiko Yasukawa Yutaka Yatomi Hitoshi Ikeda Nobutaka Hattori |
author_sort |
Shin‐Ichi Ueno |
title |
Nonmercaptalbumin as an oxidative stress marker in Parkinson’s and PARK2 disease |
title_short |
Nonmercaptalbumin as an oxidative stress marker in Parkinson’s and PARK2 disease |
title_full |
Nonmercaptalbumin as an oxidative stress marker in Parkinson’s and PARK2 disease |
title_fullStr |
Nonmercaptalbumin as an oxidative stress marker in Parkinson’s and PARK2 disease |
title_full_unstemmed |
Nonmercaptalbumin as an oxidative stress marker in Parkinson’s and PARK2 disease |
title_sort |
nonmercaptalbumin as an oxidative stress marker in parkinson’s and park2 disease |
publisher |
Wiley |
series |
Annals of Clinical and Translational Neurology |
issn |
2328-9503 |
publishDate |
2020-03-01 |
description |
Abstract Objective To investigate the oxidized albumin ratio, which is the redox ratio of human nonmercaptalbumin (HNA) to serum albumin (%HNA), as a biomarker in idiopathic Parkinson’s disease (iPD) and related neurodegenerative disorders. Methods This prospective study enrolled 216 iPD patients, 15 patients with autosomal recessive familial PD due to parkin mutations (PARK2), 30 multiple system atrophy (MSA) patients, 32 progressive nuclear palsy (PSP) patients, and 143 healthy controls. HNA was analyzed using modified high‐performance liquid chromatography and was evaluated alongside other parameters. Results iPD and PARK2 patients had a higher %HNA than controls (iPD vs. controls: odds ratio (OR) 1.325, P < 0.001; PARK2 vs. controls: OR 1.712, P < 0.001). Even iPD patients at an early Hoehn & Yahr stage (I and II) showed a higher %HNA than controls. iPD patients had a higher %HNA than MSA and PSP patients (iPD vs. MSA: OR 1.249, P < 0.001, iPD vs. PSP: OR 1.288, P < 0.05). When discriminating iPD patients from controls, %HNA corrected by age achieved an AUC of 0.750; when discriminating iPD patients from MSA and PSP patients, an AUC of 0.747 was achieved. Furthermore, uric acid, an antioxidant compound, was decreased in iPD patients, similar to the change in %HNA. Interpretation %HNA was significantly increased in iPD and PARK2 patients compared with controls, regardless of disease course and severity. Oxidative stress might be increased from the early stages of iPD and PARK2 and play an important role in their pathomechanisms. |
url |
https://doi.org/10.1002/acn3.50990 |
work_keys_str_mv |
AT shinichiueno nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease AT takuhatano nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease AT ayamiokuzumi nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease AT shinjisaiki nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease AT yutakaoji nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease AT akiomori nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease AT takahirokoinuma nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease AT motokifujimaki nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease AT harukatakeshigeamano nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease AT akihidekondo nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease AT naoyukiyoshikawa nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease AT takahironojiri nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease AT makotokurano nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease AT keikoyasukawa nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease AT yutakayatomi nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease AT hitoshiikeda nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease AT nobutakahattori nonmercaptalbuminasanoxidativestressmarkerinparkinsonsandpark2disease |
_version_ |
1721487374699986944 |